Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

March 25, 2024

Study Completion Date

November 22, 2026

Conditions
Bladder Cancer
Interventions
DRUG

Pembrolizumab

200 mg IV on day 1 and day 22

DRUG

Entinostat

5 mg given orally on day 1, day 8 and day 15

PROCEDURE

Procedure/Surgery

A radical cystectomy is a surgical procedure to remove the entire urinary bladder and maximal transurethral resection of bladder tumor (TURBT) is a surgical procedure used to remove as much of the bladder tumor as possible.

Trial Locations (2)

19111

Fox Chase Cancer Center, Philadelphia

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Syndax Pharmaceuticals

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER